@article{3021459,
    title = "Association between hsa-MIR-30e polymorphisms and sporadic primary hyperparathyroidism risk",
    author = "Mizamtsidi, M. and Nastos, K. and Palazzo, F. and Constantinides, V. and Dina, R. and Farenden, M. and Mastorakos, G. and Vassiliou, I. and Gazouli, M.",
    journal = "In vivo (Athens, Greece)",
    year = "2019",
    volume = "33",
    number = "4",
    pages = "1263-1269",
    publisher = "International Institute of Anticancer Research",
    doi = "10.21873/invivo.11598",
    keywords = "biological marker;  microRNA;  microRNA 30e;  unclassified drug;  biological marker;  microRNA;  MIRN30 microRNA, human, adult;  aged;  allele specific polymerase chain reaction;  Article;  controlled study;  differential diagnosis;  female;  gene expression;  gene frequency;  genetic association;  genetic risk;  genotype;  human;  human tissue;  major clinical study;  male;  parathyroid adenoma;  primary hyperparathyroidism;  real time reverse transcription polymerase chain reaction;  retrospective study;  risk assessment;  single nucleotide polymorphism;  adolescent;  allele;  case control study;  gene expression regulation;  genetic association study;  genetic predisposition;  genetics;  metabolism;  middle aged;  odds ratio;  primary hyperparathyroidism;  young adult, Adolescent;  Adult;  Aged;  Alleles;  Biomarkers;  Case-Control Studies;  Female;  Gene Expression Regulation, Neoplastic;  Gene Frequency;  Genetic Association Studies;  Genetic Predisposition to Disease;  Genotype;  Humans;  Hyperparathyroidism, Primary;  Male;  MicroRNAs;  Middle Aged;  Odds Ratio;  Polymorphism, Single Nucleotide;  Retrospective Studies;  Young Adult",
    abstract = "Background/Aim: Almost 15% of patients with sporadic primary hyperparathyroidism (sPHPT) present with multiple gland disease (MGD). The aim of this study was to investigate the potential role of two polymorphisms of the hsa-miR-30e, in sPHPT tumorigenesis. Patients and Methods: One-hundred twenty sPHPT patients, 77 presenting a single adenoma and 43 with MGD, and 54 healthy controls were genotyped. The SNPs were identified using the allelespecific PCR methodology, while the hsa-miR-30e expression was analyzed by real-time quantitative reverse transcriptase PCR. Results: Hsa-miR-30e expression was found to be significantly higher in patients with MGD compared to patients with single adenomas (p=0.0019), but no differences were found regarding specific genotype carriers. The genotype frequencies for ss178077483 and rs7556088 were significantly different between patients and healthy controls. Conclusion: Although the polymorphisms cannot be used as biomarkers for the differential diagnosis of MGD, hsa-miR- 30e expression could potentially serve as a biomarker for this purpose. © 2019 International Institute of Anticancer Research. All rights reserved."
}